QIAGEN N.V. (QGEN) recently announced that Bode Technology will be the exclusive global commercial partner for its GEDmatch PRO genealogy database. QIAGEN’s subsidiary Verogen inked the deal with Bode. The company has been providing GEDmatch PRO to customers since the acquisition of its subsidiary, Verogen, in early 2023.The latest partnership is aimed at accelerating the use of QIAGEN’s next-generation sequencing (NGS) products in human identification (HID) and forensic investigations.QGEN’s Likely Stock T ...

Venlo, the Netherlands, and Germantown, Maryland, Sept. 23, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Bode Technology, the largest private U.S. forensics laboratory company with a growing presence in other regions, would become the exclusive global commercial partner for the GEDmatch PRO genealogy database, which is used to assist police and forensic teams with investigative comparisons of genetic data. The multi-year agreement between QIAGEN’s su ...

QIAGEN N.V. (QGEN) recently announced the launch of 100 new assays for its digital polymerase chain reaction (dPCR) platform — QIAcuity. The assays will be used to study cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring. These are available through QIAGEN’s comprehensive GeneGlobe platform.The latest launch will be an addition to the company’s PCR product portfolio.QGEN’s Likely Stock Trend Following the NewsShares of QGEN were up 0.04% in pre-market ...

Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital PCR (dPCR) platform QIAcuity for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring. These new assays are available through QIAGEN’s comprehensive GeneGlobe platform which integrates pre-designed assays with a database of more than 10,0 ...

QIAGEN’s (QGEN) business is expected to get a boost from its growing molecular diagnostic market, expanded test menu and growth-driving strategic collaborations. Yet, a challenging macro environment and an intensely competitive market may dent its results of operations. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving Growth for QGEN StockQIAGEN offers one of the broadest portfolios of molecular technologies for healthcare. Its range of assays for diseases and biomarkers speeds up and simp ...

QIAGEN N.V. (QGEN) announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian Ministry of Health. Initiated in 2009, the expanded collaboration allows Bio-Manguinhos to launch an advanced PCR (Polymerase Chain Reaction)-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, a capability previously unavailable in Brazil’s blood donation program. The recent development will also support ep ...

Venlo, the Netherlands, Rio de Janeiro, Brazil, Sept. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinh ...

文章核心观点 - QIAGEN与Eli Lilly合作开发QIAstat-Dx体外诊断(IVD)检测板用于检测载脂蛋白E(APOE)基因型 [1][2] - QIAstat-Dx IVD检测板是首个商业化的APOE基因型检测IVD产品 [2] - 该合作有助于增强QIAGEN的分子诊断业务 [1] 根据相关目录分别进行总结 QIAGEN与Eli Lilly的合作 - 合作开发的QIAstat-Dx IVD检测板可以为阿尔茨海默病患者的诊疗提供有价值的洞见 [2] - 该检测板可检测所有APOE基因型(APOE2、APOE3、APOE4) [2] - 携带APOE4基因型的人更易发展阿尔茨海默病且发病更早 [2] - 该检测板将与QIAGEN的多重检测平台QIAstat-Dx整合 [2] QIAstat-Dx系统 - QIAstat-Dx系统设计用于实验室使用,采用成本高效的一次性盒式测试 [3] - 该系统在传染病检测领域已有超过4000台仪器部署 [3] - 现正扩展至其他疾病和应用领域 [3] QIAGEN的合作历史 - QIAGEN拥有30多个主要合作协议,旨在推动诊断测试的开发和商业化 [4] - QIAGEN提供多种技术,包括NGS、PCR和数字PCR,以及从液体活检到组织的各种样本类型 [4] - QIAGEN已有14个FDA批准的PCR伴随诊断,涵盖癌症和帕金森病等疾病领域 [4] 行业前景有利于QIAGEN - 根据Verified Market Reports,APOE基因型检测试剂盒市场规模预计将从2023年的12亿美元增长到2030年的27亿美元,复合年增长率为12.28% [5] - 推动市场增长的关键因素包括对遗传检测和个性化医疗的认知度提高,以及心血管疾病和神经退行性疾病(如阿尔茨海默病)发病率上升 [7] - 遗传检测技术进步和预防性医疗的趋势也为市场增长做出贡献 [7] QIAGEN的其他最新动态 - 与阿斯利康扩大主合作协议,开发和商业化后者针对慢性疾病的伴随诊断 [8] - 在美国推出QIAstat-Dx肠胃疾病检测板2代,获FDA批准用于临床 [8] QIAGEN股价表现 - 过去一年QGEN股价上涨0.6%,而同期行业下跌1.8% [9]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senio ...

文章核心观点 - 公司拟发行7年期无担保可转换债券 总额4.5亿美元 [1][2][3] - 债券转股价较参考股价有42.5%-47.5%的溢价 [3] - 公司拟将募集资金用于一般公司用途 包括偿还现有债务 [4] - 债券将在法兰克福证券交易所公开市场上市交易 [4] 公司概况 - 公司是全球领先的"样品到洞见"解决方案提供商 [6][7] - 公司为超过50万客户提供分子诊断和生命科学领域的解决方案 [7] - 截至2024年6月30日 公司在全球35个国家拥有5,900多名员工 [7] 发行细节 - 债券将以最低20万美元的面值发行 [2] - 债券票面利率为2.125%-2.625% 每半年付息一次 [3] - 公司可于2029年10月1日后赎回全部未转股债券 [3] - 债券持有人可于发行5周年要求提前赎回 [3]